Platelet aggregation and atherosclerosis.
The relationship of platelet aggregation to coronary and cerebral ischemic attacks has been well established. A number of clinical trials have shown that the daily use of aspirin 160 to 325 mg daily, dipyridamole 300 to 400 mg daily, or both are effective in preventing platelet aggregation, and results in a statistically significantly reduction in the incidence of coronary events and transient ischemic cerebral attacks.
D001161:Arteriosclerosis / Q000097:blood; D001241:Aspirin / Q000627:therapeutic use; D004176:Dipyridamole / Q000627:therapeutic use; D004562:Electrocardiography; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D010974:Platelet Aggregation / Q000187:drug effects*; D013442:Sulfinpyrazone / Q000627:therapeutic use
D004176:Dipyridamole; D001241:Aspirin; D013442:Sulfinpyrazone